# Cancer biotherapy & radiopharmaceuticals

Source: https://nuclide.cc/journals/cancer-biotherapy-and-radiopharmaceuticals/  
Nuclide record `cancer-biotherapy-and-radiopharmaceuticals` (Journal). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)"; commercial use needs a licence.

## TL;DR

Cancer Biotherapy and Radiopharmaceuticals covers immunotherapy, targeted biological agents and radiolabelled drugs for cancer imaging and treatment, read by nuclear medicine and biotherapy researchers.

## Summary

Cancer Biotherapy & Radiopharmaceuticals has been published since 1996 and, according to the NLM catalogue, is issued from 2026 by SAGE Publications in Thousand Oaks, California, following its long run with Mary Ann Liebert; Crossref lists SAGE Publications as the publisher. As its title indicates, its two subjects are cancer biotherapy, meaning biological agents used to treat cancer, and radiopharmaceuticals, meaning radiolabelled compounds used to image and treat it. The NLM record lists it as a United States serial that is indexed in MEDLINE; it is not listed in DOAJ.

## Fields

- Kind: Journal
- Last checked: 2026-09-10
- Also known as: Cancer Biotherapy & Radiopharmaceuticals; Cancer Biotherapy and Radiopharmaceuticals; Cancer Biother Radiopharm
- Publisher: SAGE Publications (formerly Mary Ann Liebert)
- Scope: cancer biotherapy and radiopharmaceuticals

## Sources

- Homepage: https://journals.sagepub.com/home/cbr
- NLM Catalog: https://www.ncbi.nlm.nih.gov/nlmcatalog/9605408

## Connected records

- technologies: [Radio-antibody & radio-ADC](https://nuclide.cc/technologies/radioimmunotherapy/), [Radioligand therapy (beta emitters)](https://nuclide.cc/technologies/radioligand-therapy/)

---
JSON: https://nuclide.cc/api/v1/entities/cancer-biotherapy-and-radiopharmaceuticals.json